NO20051966L - Nye pyrimidinamidderivater og anvendelse derav - Google Patents

Nye pyrimidinamidderivater og anvendelse derav

Info

Publication number
NO20051966L
NO20051966L NO20051966A NO20051966A NO20051966L NO 20051966 L NO20051966 L NO 20051966L NO 20051966 A NO20051966 A NO 20051966A NO 20051966 A NO20051966 A NO 20051966A NO 20051966 L NO20051966 L NO 20051966L
Authority
NO
Norway
Prior art keywords
derivatives
pyrimidinamide
disease
new
benzoylaminophenyl
Prior art date
Application number
NO20051966A
Other languages
English (en)
Inventor
Pascal Furet
Werner Breitenstein
Paul William Manley
Sandra Jacob
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20051966(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20051966L publication Critical patent/NO20051966L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Det beskrives nye substituerte N-(3-benzoyIaminofenyl)-4-pyridyl-2-pyrimidinaminderivater, fremgangsmåter for fremstilling derav, farmasøytiske preparater inneholdende disse, anvendelsen derav eventuelt i kombinasjon med en eller flere andre farmasøytiske aktive forbindelser for behandling av en sykdom som responderer på en inhibering av proteinkinaseaktivitet, spesielt en neoplastisk sykdom, og en fremgangsmåte for behandling av en slik sykdom.
NO20051966A 2002-09-27 2005-04-22 Nye pyrimidinamidderivater og anvendelse derav NO20051966L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0222514.2A GB0222514D0 (en) 2002-09-27 2002-09-27 Organic compounds
PCT/EP2003/010724 WO2004029038A1 (en) 2002-09-27 2003-09-26 Novel pyrimidineamide derivatives and the use thereof

Publications (1)

Publication Number Publication Date
NO20051966L true NO20051966L (no) 2005-04-22

Family

ID=9944917

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051966A NO20051966L (no) 2002-09-27 2005-04-22 Nye pyrimidinamidderivater og anvendelse derav

Country Status (23)

Country Link
US (1) US7655669B2 (no)
EP (1) EP1546127B1 (no)
JP (2) JP4463685B2 (no)
KR (2) KR100876055B1 (no)
CN (1) CN100404528C (no)
AT (1) ATE369355T1 (no)
AU (1) AU2003270277B2 (no)
BR (1) BR0314797A (no)
CA (1) CA2499822C (no)
DE (1) DE60315479T2 (no)
DK (1) DK1546127T3 (no)
EC (1) ECSP055701A (no)
ES (1) ES2288615T3 (no)
GB (1) GB0222514D0 (no)
MX (1) MXPA05003253A (no)
NO (1) NO20051966L (no)
NZ (1) NZ538930A (no)
PL (1) PL374443A1 (no)
PT (1) PT1546127E (no)
RU (1) RU2378267C2 (no)
SI (1) SI1546127T1 (no)
WO (1) WO2004029038A1 (no)
ZA (1) ZA200502304B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
US7232825B2 (en) * 2003-05-02 2007-06-19 Guoqing P Chen Phenylaminopyrimidine derivatives and methods of use
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
MX2007002434A (es) 2004-08-31 2007-05-04 Astrazeneca Ab Derivados de quinazolinona y su uso como inhibidores de b-raf.
US7939541B2 (en) 2004-09-09 2011-05-10 Natco Pharma Limited Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
BRPI0515081B8 (pt) * 2004-09-09 2021-05-25 Natco Pharma Ltd composto, processo para a preparação de um sal de guanidino trifluormetilaroil amida, processo para a preparação de um fenil amino pirido pirimidina, composições farmacêuticas e processos para preparar (3,5-bis trifluormetil)-n-[4-metil-3-(4-piridin-3-il-pirimidin-2-ilamino)-fenil]-benzamida
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
CN1972917B (zh) * 2004-12-31 2010-08-25 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
CN1939910A (zh) 2004-12-31 2007-04-04 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
BRPI0606872A2 (pt) 2005-01-28 2009-07-21 Novartis Ag uso de pirimidilaminobenzamidas para o tratamento de doenças que respondem à modulação de atividade de tie-2 quinase
MY146795A (en) * 2005-06-09 2012-09-28 Novartis Ag Process for the synthesis of organic compounds
WO2008020203A1 (en) * 2006-08-17 2008-02-21 Astrazeneca Ab Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors
KR20090065512A (ko) 2006-09-22 2009-06-22 노파르티스 아게 Ａｂｌ 티로신 키나제 억제제에 의해 필라델피아-양성 백혈병의 치료를 최적화시키는 방법
AU2007317349B2 (en) * 2006-11-03 2011-10-20 Irm Llc Compounds and compositions as protein kinase inhibitors
US7550591B2 (en) * 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
EP2152688A1 (en) 2007-05-04 2010-02-17 Irm Llc Compounds and compositions as c-kit and pdgfr kinase inhibitors
WO2008137605A1 (en) * 2007-05-04 2008-11-13 Irm Llc Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
EP2152079A4 (en) * 2007-06-04 2011-03-09 Avila Therapeutics Inc HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2009026204A1 (en) 2007-08-22 2009-02-26 Irm Llc 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
KR20120107538A (ko) 2007-08-22 2012-10-02 아이알엠 엘엘씨 키나제 억제제로서의 5-(4-(할로알콕시)페닐)피리미딘-2-아민 화합물 및 조성물
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
SG185664A1 (en) * 2010-05-11 2012-12-28 Mahesh Kandula 4, 6 -dibenzoylamino- 2 -methyl- pyrimidine derivatives and their use for the treatment of cancer
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
US20220048893A1 (en) * 2019-03-05 2022-02-17 Hongyi & Associates Llc Compounds for Treating Neurodegenerative Diseases and Cancers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135699T1 (de) 1986-01-13 1996-04-15 American Cyanamid Co 4,5,6-substituierte 2-pyrimidinamine
US5215989A (en) * 1989-12-08 1993-06-01 Merck & Co., Inc. Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
TW225528B (no) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
JPH08503971A (ja) 1993-10-01 1996-04-30 チバ−ガイギー アクチェンゲゼルシャフト ピリミジンアミン誘導体及びその調製のための方法
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
GB0025820D0 (en) 2000-10-20 2000-12-06 Novartis Ag Organic compounds
CA2446939C (en) 2001-05-16 2005-08-02 Matthias Stein-Gerlach Pyridylpyrimidine derivatives as effective compounds against prion diseases
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
EP1700164B1 (en) 2003-12-23 2010-08-04 Koninklijke Philips Electronics N.V. Irradiation method

Also Published As

Publication number Publication date
NZ538930A (en) 2008-04-30
RU2005113153A (ru) 2006-11-10
CA2499822A1 (en) 2004-04-08
ZA200502304B (en) 2006-04-26
AU2003270277A1 (en) 2004-04-19
JP4463685B2 (ja) 2010-05-19
RU2378267C2 (ru) 2010-01-10
PT1546127E (pt) 2007-11-07
CN1684951A (zh) 2005-10-19
HK1080459A1 (en) 2006-04-28
GB0222514D0 (en) 2002-11-06
EP1546127B1 (en) 2007-08-08
CN100404528C (zh) 2008-07-23
BR0314797A (pt) 2005-07-26
DE60315479T2 (de) 2008-04-30
US20060142577A1 (en) 2006-06-29
ATE369355T1 (de) 2007-08-15
AU2003270277B2 (en) 2007-08-23
CA2499822C (en) 2012-04-10
KR20050047128A (ko) 2005-05-19
US7655669B2 (en) 2010-02-02
WO2004029038A1 (en) 2004-04-08
DE60315479D1 (de) 2007-09-20
DK1546127T3 (da) 2007-12-10
KR100876055B1 (ko) 2008-12-26
JP5178681B2 (ja) 2013-04-10
KR20070098940A (ko) 2007-10-05
PL374443A1 (en) 2005-10-17
EP1546127A1 (en) 2005-06-29
ECSP055701A (es) 2005-05-30
MXPA05003253A (es) 2005-06-08
SI1546127T1 (sl) 2008-08-31
JP2006508064A (ja) 2006-03-09
ES2288615T3 (es) 2008-01-16
JP2010043113A (ja) 2010-02-25

Similar Documents

Publication Publication Date Title
DK1546127T3 (da) Nye pyrimidinamidderivater og anvendelse deraf
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
DK1636236T3 (da) Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer
WO2004005281A8 (en) Inhibitors of tyrosine kinases
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
NO20040547L (no) Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse.
ATE408601T1 (de) Fredericamycin-derivate
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
BR0312722A (pt) Derivados de pirazol heterobicìclico como inibidores de qinase
SE0101932D0 (sv) Pharmaceutical combinations
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
DK1404304T3 (da) Tablet omfattende cetirizin og pseudoephedrin
SE0002729D0 (sv) Novel compound form
DE50312224D1 (de) Deuterierte catecholaminderivate sowie diese verbindungen enthaltende arzneimittel
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
NO20030021D0 (no) Heterosykliske forbindelser som er inhibitorer for enzymet DPP-IV
TW200700075A (en) Roflumilast and integrin inhibitor combination and method of treatment
NO20034985D0 (no) Nye 5-tio-SS-D-xylopyranosid-derivater, fremgangsmåte for fremstilling derav, farmasöytiske blandinger inneholdende dem og den terapeutiskeanvendelse derav
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
DE50304524D1 (de) Arzneimittel enthaltend substituierte 2,5-diaminomethyl-1h-pyrrole
ECSP12005525A (es) Inhibidores de cinasas de tirosina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application